A Leading Edge COVID-19 Response
As a drug re-purposing company, we investigate approved drugs with established safety histories for new disease applications, moving them efficiently and safely into new human trials, developing new formulations, and seeking new regulatory approvals in global markets.
Our program specifically investigates compounds that have never been approved in the U.S. or Europe, and we have protected our lead compounds with both method of use and new composition of matter patents for their derivatives and analogues.
We are moving aggressively to expand the investigation of our lead repurposed drug compound Ifenprodil as a new therapeutic treatment for COVID-19, in addition to acute lung injury (ALI). Please click here to view a short clip on Algernon’s Pre-IND Application with the U.S. FDA.
The below presentation summarizes our history with Ifenprodil, our confidence in its potential for use in immediate phase 2 clinical trials for the treatment of COVID-19, and the steps we have been taking towards achieving this.
Christopher J. Moreau
Chief Executive Officer
Mark Williams, PhD, MBA
Chief Science Officer